Ver
Oncology spending will reach $100Bn globally by 2018, an
absolute growth of $30-40Bn, driven by
greater numbers of drug approvals and an increase in cancer incidence.
Oncology innovation is energized by a number of
immunotherapies, many of which have FDA Breakthrough Therapy Designation, with
the potential for multiple follow-on indications, deepening an already full
pipeline.
Ver:
Global Outlook for Medicines Through 2018. Report by the IMS
Ver:
Global Outlook for Medicines Through 2018. Report by the IMS
No hay comentarios:
Publicar un comentario